News & Updates
Showing Oncology articles
Showing
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
08 Jul 2026
MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM
In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).
MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM
08 Jul 2026
Rucaparib extends time to subsequent therapy in advanced ovarian cancer
In patients with newly diagnosed advanced ovarian cancer, treatment with rucaparib delays the median time to first and second subsequent anticancer therapy for almost 1 year relative to placebo, according to a study presented at ESMO Gyn 2026.
Rucaparib extends time to subsequent therapy in advanced ovarian cancer
02 Jul 2026
Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer
Treatment with dostarlimab combined with carboplatin and paclitaxel (CP) confers sustained long-term progression-free survival (PFS) and overall survival (OS) benefits on patients with primary advanced or recurrent deficient mismatch repair and microsatellite instability-high (dMMR/MSI-H) endometrial cancer, as shown by the results of the phase III RUBY trial.
